Posted by Michael Wonder on 12 Jun 2018
ICER's updated assessment of new targeted therapies for plaque psoriasis notes minor distinctions in effectiveness, while recent price hikes have made entire drug class less cost-effective
12 June 2018 - Value-based price benchmarks for new IL-23 agents range from $25,000-$42,000 per year, which would require a discount of 37%-57% from the list price of guselkumab, the only drug in this group currently priced in the market.
The Institute for Clinical and Economic Review (ICER) today released a condition update report assessing the comparative clinical effectiveness and value of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis.
ICER previously reviewed treatments for plaque psoriasis in 2016. In addition to incorporating new clinical data and updated costs for previously reviewed therapies, this condition update includes analyses of the recently approved medications guselkumab (Tremfya, Johnson & Johnson), tildrakizumab (Ilumya, Sun Pharma/Merck), and certolizumab pegol (Cimzia, UCB), as well as risankizumab (AbbVie), which was recently filed for review by the FDA.
